These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37385541)

  • 1. Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome.
    Colucci M; Angeletti A; Zotta F; Carsetti R; Lugani F; Ravà L; Ravani P; Emma F; Ghiggeri GM; Vivarelli M
    Kidney Int; 2023 Sep; 104(3):577-586. PubMed ID: 37385541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P; Bonanni A; Ghiggeri GM
    BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome.
    Colucci M; Carsetti R; Serafinelli J; Rocca S; Massella L; Gargiulo A; Lo Russo A; Capponi C; Cotugno N; Porzio O; Onetti Muda A; Palma P; Emma F; Vivarelli M
    Front Immunol; 2019; 10():1653. PubMed ID: 31379849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.
    Fribourg M; Cioni M; Ghiggeri G; Cantarelli C; Leventhal JS; Budge K; Bin S; Riella LV; Colucci M; Vivarelli M; Angeletti A; Perin L; Cravedi P
    Front Immunol; 2021; 12():726428. PubMed ID: 34621271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.
    Bertrand Q; Mignot S; Kwon T; Couderc A; Maisin A; Cambier A; Baudouin V; Peyneau M; Deschênes G; Hogan J; Dossier C
    Pediatr Nephrol; 2022 Feb; 37(2):357-365. PubMed ID: 34132894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
    Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
    Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
    BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
    Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.
    Colucci M; Carsetti R; Cascioli S; Casiraghi F; Perna A; Ravà L; Ruggiero B; Emma F; Vivarelli M
    J Am Soc Nephrol; 2016 Jun; 27(6):1811-22. PubMed ID: 26567244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome.
    Casiraghi F; Todeschini M; Podestà MA; Mister M; Ruggiero B; Trillini M; Carrara C; Diadei O; Villa A; Benigni A; Remuzzi G
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
    Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital.
    Guzmán Morais B; Ordóñez Álvarez FÁ; Santos Rodríguez F; Martín Ramos S; Fernández Novo G
    An Pediatr (Engl Ed); 2022 Feb; 96(2):83-90. PubMed ID: 35144901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
    Bonanni A; Calatroni M; D'Alessandro M; Signa S; Bertelli E; Cioni M; Di Marco E; Biassoni R; Caridi G; Ingrasciotta G; Bertelli R; Di Donato A; Bruschi M; Canepa A; Piaggio G; Ravani P; Ghiggeri GM
    Br J Clin Pharmacol; 2018 Jun; 84(6):1238-1249. PubMed ID: 29436729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome.
    Dossier C; Prim B; Moreau C; Kwon T; Maisin A; Nathanson S; De Gennes C; Barsotti K; Bourrassi A; Hogan J; Deschênes G
    Pediatr Nephrol; 2021 May; 36(5):1175-1182. PubMed ID: 33118048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome.
    Bhatia D; Sinha A; Hari P; Sopory S; Saini S; Puraswani M; Saini H; Mitra DK; Bagga A
    Pediatr Res; 2018 Oct; 84(4):520-526. PubMed ID: 29983411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.